Predictive accuracy of elevated mitotic rate on lymph node positivity and recurrence in thin melanomas

Background Mitotic rate (MR) is considered an important prognostic factor for melanoma but is not currently used for staging because its nuanced effect is not yet well-delineated. We sought to determine if T category-specific MR is predictive of sentinel lymph node (SLN) positivity, recurrence, and melanoma-specific mortality (MSM). Methods A retrospective review of patients with primary cutaneous melanoma from 1994 to 2020 at a single academic center was performed. Patient demographics and tumor characteristics were recorded. MR was considered elevated for each AJCC8-defined T category if it was ≥2 mitoses/mm2 for T1, ≥4 mitoses/mm2 for T2, ≥6 mitoses/mm2 for T3, or ≥7 mitoses/mm2 for T4. Statistical analysis was performed to assess the predictive accuracy of MR on selected outcomes while controlling for ulceration. Results Data from 2,984 patients with complete records were analyzed. Along with Breslow thickness and ulceration, elevated MR was associated with higher risk of MSM (HR 1.816, P=0.0001). There was no difference among patients with ulcerated T1 or T2 tumors regardless of MR, but those with non-ulcerated T1 or T2 tumors and elevated MR were more likely to have positive SLNs (P<0.0001 and P=0.0043, respectively) and recurrence (P=0.0007 and P=0.0004, respectively) compared to counterparts with low MR. There were no notable differences for T3 or T4 tumors based on MR. Conclusions Elevated MR is associated with SLN positivity and recurrence in thin melanomas, independent of ulceration. SLN biopsy should therefore be strongly considered for patients with non-ulcerated lesions <0.8 mm thick if the MR is ≥2 mitoses/mm2.

[1]  M. Marchetti,et al.  Utility of a Model for Predicting the Risk of Sentinel Lymph Node Metastasis in Patients With Cutaneous Melanoma. , 2022, JAMA dermatology.

[2]  M. Rugge,et al.  Prognosis for Cutaneous Melanoma by Clinical and Pathological Profile: A Population-Based Study , 2021, Frontiers in Oncology.

[3]  F. Tas,et al.  Different mitotic rates are associated with different prognostic factors, relapses, and survival rates in melanoma , 2021, International journal of dermatology.

[4]  L. Dennis,et al.  Age and Cohort Trends of Malignant Melanoma in the United States , 2021, Cancers.

[5]  K. Shannon,et al.  Reappraisal of the prognostic significance of mitotic rate supports its reincorporation into the melanoma staging system , 2020, Cancer.

[6]  A. Abbott,et al.  High Mitotic Rate Predicts Sentinel Lymph Node Involvement in Thin Melanomas. , 2020, The Journal of surgical research.

[7]  R. Scolyer,et al.  Melanoma pathology reporting and staging , 2019, Modern Pathology.

[8]  J. N. Rodríguez-López,et al.  Mitotic rate as an important prognostic factor in cutaneous malignant melanoma , 2019, Clinical and Translational Oncology.

[9]  J. Gershenwald,et al.  The eighth edition American Joint Committee on Cancer (AJCC) melanoma staging system: implications for melanoma treatment and care , 2018, Expert review of anticancer therapy.

[10]  R. Scolyer,et al.  Melanoma Staging: American Joint Committee on Cancer (AJCC) 8th Edition and Beyond , 2018, Annals of Surgical Oncology.

[11]  A. Moradi,et al.  The relationship between mitotic rate and depth of invasion in biopsies of malignant melanoma , 2018, Clinical, cosmetic and investigational dermatology.

[12]  J. Gershenwald,et al.  Clinical impact of ulceration width, lymphovascular invasion, microscopic satellitosis, perineural invasion, and mitotic rate in patients undergoing sentinel lymph node biopsy for cutaneous melanoma: a retrospective observational study at a comprehensive cancer center , 2018, Cancer medicine.

[13]  L. Wheless,et al.  Mitotic rate is associated with positive lymph nodes in patients with thin melanomas , 2017, Journal of the American Academy of Dermatology.

[14]  J. Kirkwood,et al.  Sentinel Lymph Node Biopsy and Management of Regional Lymph Nodes in Melanoma: American Society of Clinical Oncology and Society of Surgical Oncology Clinical Practice Guideline Update , 2018, Annals of Surgical Oncology.

[15]  Jeffrey E Gershenwald,et al.  Melanoma staging: Evidence‐based changes in the American Joint Committee on Cancer eighth edition cancer staging manual , 2017, CA: a cancer journal for clinicians.

[16]  A. Weaver,et al.  Survival of cutaneous melanoma based on sex, age, and stage in the United States, 1992–2011 , 2017, Cancer medicine.

[17]  J. Coebergh,et al.  Gender differences in melanoma survival: female patients have a decreased risk of metastasis. , 2011, The Journal of investigative dermatology.

[18]  Jeffrey E Gershenwald,et al.  Final version of 2009 AJCC melanoma staging and classification. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  Sing Kai Lo,et al.  Interobserver Reproducibility of Histopathologic Prognostic Variables in Primary Cutaneous Melanomas , 2003, The American journal of surgical pathology.

[20]  S. Leeder,et al.  A population based study , 1993, The Medical journal of Australia.

[21]  B K Armstrong,et al.  Melanoma of the skin. , 1984, British medical bulletin.